跳至主要内容

Animal Models for Anxiety and Depression

 Stress, anxiety and depression are closely related to the phenomenon, most of the anxiety and depression patients have experienced severe psychological stress events. Thus, stress events are seen as a cause of anxiety and depression, or at least on genetic basis, which can lead to the generation of emotional disorders. Anxiety and Depression Animal models place animals in a series of stress situations (latent or actual threats, acute or chronic) that cause emotional disorders and then apply specific measures to behavioral and physiological indicators Detection, and thus explore the mechanisms of this emotional disorder, as well as the identification and screening of anxiolytics or antidepressants.

Anxiety Animal Model: Anxiety is a pre-known but inevitable, upcoming stress events caused by an expected response to fear, fear, tension and other psychiatric symptoms as the main performance, accompanied by palpitations, sweating, cold hands and feet and other plant neurological disorders, the core symptoms of concern.

In order to prove whether the anxiety model stimulates the animal's anxiety response should be looking for ways to measure the anxiety response and indicators; the animal's anxiety response is usually measured using animal behavior or physiological responses to stress or new heterosexual events. These disgusting situations of the animal include open spaces, bright or have a certain height, all of which form the basis for the use of inquiry tests to measure animal anxiety reactions.

Animal Models for Anxiety and Depression
The main behavioral indicators include: (1) the inhibition of exploratory behavior, the number of animals to explore the open arm decreased, the time to stay in the open arm to reduce the number of lattice reduction, animals to avoid the bright place; (2) social behavior reduction, mutual sniffing, (3) mutual chase the behavior was significantly reduced, the animals tend to escape other animals.

Depression Animal model: depression shows a depression, slow thinking, and slow behavior as the main symptoms of mental illness, and may be accompanied by reduced sleep, weight and other physical symptoms, uncontrollable stress is an important reason for its production. Thus, the common characteristic of all depressive animal models is that depressive behavior is caused by uncontrollable negative events. At present, the establishment of depression animal models is divided into three categories: behavioral despair, acquired helplessness and chronic mild unpredictable stress.

Medicilon's Pharmacology department functions in accordance with the needs of our customers for a variety of effective animal models used to detect drug effectiveness. We offer non-human primates, dogs, mice and rats, rabbits, guinea pigs and others in our services.  At present, we have various proven effective animal models.  Furthermore, our experienced staffs operate with strong theoretical basis.  We offer the services which are flexible for custom development of various types of models to meet the requirements of our clients.

Recently, Medicilon appointment Dr. Dong Wenxin as the company's senior director of pharmacology team. Dr. Dong has long been engaged in pharmacological research, mainly related to depression, Alzheimer's disease, pain, anxiety, Parkinson's disease and other fields.

We believe that the addition of Dr. Dong will greatly contribute to the business development and strategic planning of the Medicilon pharmacological team, to further expand the Medicilon effective animal model service platform, improve Medicilon's effective animal model library to meet the different types of customers new drug research and development needs.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati